No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
about
Diabetes mellitus and metformin in hepatocellular carcinomaKASL clinical practice guidelines: management of chronic hepatitis BEfficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-AnalysisManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesEfficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settingsRecent advances in micro/nanotechnologies for global control of hepatitis B infectionEfficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.Clinical implications of hepatitis B virus mutations: recent advances.Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.A cutting-edge view on the current state of antiviral drug development.Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.Dried blood spot sampling for hepatitis B virus serology and molecular testingLong-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis BTenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and SafetySimilar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B.Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patientsRandomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovirComparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patientsKASL Clinical Practice Guidelines: Management of chronic hepatitis B.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis BEvaluation of antiviral resistant hepatitis B virus subpopulations in patients with chronic hepatitis B by using terminal restriction fragment length polymorphism.Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysisTenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failuresLow-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.Therapeutic advances in the management of chronic hepatitis B infection.Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma.The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4(+)CD25(+) regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment.Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load.Treatment of Hepatitis B: A Concise Review.Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA.Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2.Patients with hematological malignancies and serological signs of prior resolved hepatitis B.First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practiceTenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
P2860
Q26741205-C44FBE1F-2D12-4777-AA3E-15E34EE4E8AEQ26752475-D1AB51CC-C222-4176-9D2E-33586F118D88Q26765932-6F061F48-8C6B-412A-AC20-1ED8D4674629Q27000080-EE735EE4-B472-4A2D-85AC-4355628FBA1FQ28540372-8D42CE2F-7D9F-4A86-8D37-A58B75B80A5FQ30394611-B83156B2-6131-4F39-B256-2061D0339F6EQ33608997-FC4731A7-019B-4C55-9ABB-F78C238186B7Q33801311-1C2FBD3F-FE88-4565-A6CA-F0FC0B6814A0Q33857643-5B1E8274-C067-4619-AEC1-C3B7B3AAEB5CQ34036018-23FD923A-8E6B-4FD6-B512-D6EABDFA316DQ34364620-07E0F11D-083E-4E37-8DD4-921B8868C1D8Q34684010-3BD9C520-CAE3-4972-AE5F-9CB62190B0DBQ34948124-055EF8BD-12D3-421C-971D-9AA7F78F1FA0Q35105892-AE488FD7-22A9-4A6C-8596-0FA763A621F5Q35152367-1C8D7B86-6132-4A3D-97ED-3630BA72FC2EQ35535861-15682C92-8AE9-4D3D-AD09-F5A06617B843Q35594210-7A9C002C-B153-40C6-BB11-6D27EF6B535BQ35681979-6E901F60-9956-4E94-A05F-6C1657A344DDQ36018658-488D28EC-8149-4C45-B61B-41714DA11C9AQ36140470-99EDBF55-80D8-48D3-BDC6-E620A0DA6BE3Q36153966-7C1F4B25-6A3C-4EF0-8A90-508EDC0ECF9DQ36238754-5A518448-0F15-4959-954D-965CCC812C82Q36330265-5C233420-95EB-48D8-816C-A36D102C1B96Q36492635-5D47875D-BBB3-402F-B07B-BE19EC0D6E81Q36492640-771DEFC6-1494-4DCD-AD32-5341A74E77B0Q36505336-0F2A9F3B-E7A1-4300-A41F-85C513943383Q36757579-513CA29E-BBEA-4D47-843E-E6E5A9FCD7DFQ36950984-FE61973C-0388-407F-9B92-8E0841FD966FQ36969950-9BB507FE-9510-4C50-8698-1984C24BC5CCQ36971785-E6E3DC83-2278-472F-ACB9-CA505E07AAFAQ37195548-4CAD3236-A9E7-4CA4-9FCB-2C67AA63853AQ37284974-774B25EF-A890-4505-84E4-278317D8F697Q37346823-5AC6CF3A-6070-4059-AFDF-80C2552D4E4BQ37620340-ED2C3838-1FDF-4F7D-A66D-C64488282E60Q37722853-39A4847B-A59E-492F-A268-5DC8692C65A7Q37970447-57C3382B-E53D-4A0A-83E2-8C5BD90DDB70Q37979703-6DA9438D-C309-45DC-B501-97A18BA427B4Q37999022-33D195AB-08C8-4FA8-B42C-6E037177DE17Q38008777-8DE089E5-0649-4DFF-834A-58CB57A65EA0Q38009758-1791C90D-F8B6-4A52-AA61-539DC279061F
P2860
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@en
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@nl
type
label
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@en
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@nl
prefLabel
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@en
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@nl
P2093
P2860
P356
P1433
P1476
No resistance to tenofovir dis ...... ith chronic hepatitis B virus.
@en
P2093
Andrea Snow-Lampart
Brandi Chappell
Evguenia S Svarovskaia
Florence Myrick
James Schawalder
Jeff Sorbel
Jenny Heathcote
Kathryn Kitrinos
Katyna Borroto-Esoda
Maria Curtis
P2860
P304
P356
10.1002/HEP.24078
P407
P577
2010-12-22T00:00:00Z